Hansa Biopharma interim report January-March 2024
• Strong sales performance and solid momentum with the Phase 3 trial in anti-GBM disease • Cash runway extended into 2026• Evan Ballantyne joins Hansa Biopharma as Chief Financial OfficerLund, Sweden, April 18, 2024, Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and year-end report for January to March 2024. Highlights for the first quarter of 2024 · Strong commercial performance. Total Q1 revenue of SEK 56m including product sales of SEK 47m – sales growth during Q1 2024 was driven